flizasertib

{
  "id": "MLC-T-ONC-013618",
  "term": "flizasertib",
  "field": "Oncology and biomedicine",
  "definition": "An orally available inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, flizasertib inhibits RIP1-mediated signaling, which may preserve intestinal stem cells (ISCs) and prevent RIP1-mediated gastrointestinal (GI) damage in acute graft-versus-host disease (GvHD). RIP1 plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition.",
  "synonyms": [
    "RIP1 kinase inhibitor GDC-8264",
    "RIPK1 inhibitor GDC-8264",
    "RIP1 Inhibitor GDC-8264"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/flizasertib/"
}